Rockefeller Capital Management’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Rockefeller Capital Management’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50	Closed	-$60	–	4868
2026 Q1	$60	Buy	+50	New	+$67	﹤0.01%	4650

Other funds holding TLSIW

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return

Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Rockefeller Capital Management's TLSIW Position: Q2 2026 in Review

Rockefeller Capital Management sold out of TriSalus Life Sciences Warrant (TLSIW) in Q2 2026, closing a stake of 50 shares — an estimated $60 sold.

Rockefeller Capital Management first reported a position in TLSIW in Q1 2026 and held it in 1 quarter. The position peaked at $60 in Q1 2026. 5 funds tracked by Wall St. Rank hold TLSIW as of Q2 2026.

Rockefeller Capital Management reported no remaining TriSalus Life Sciences Warrant position as of Q2 2026 after selling out during the quarter.
Rockefeller Capital Management sold 50 TriSalus Life Sciences Warrant shares in Q2 2026, an estimated $60.
Rockefeller Capital Management first reported a position in TriSalus Life Sciences Warrant in Q1 2026 and held it in 1 quarter.
Rockefeller Capital Management's TriSalus Life Sciences Warrant position peaked at $60 in Q1 2026.
5 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.